Haemophilus b Conjugate Vaccine

**Act-HIB®**  Supplier: Sanofi Pasteur Limited
**HIBERIX®**  Supplier: GlaxoSmithKline Inc.

**INDICATIONS:**

- Children 2-59 months of age
- Individuals 5 years of age and older with anatomic or functional asplenia or congenital immunodeficiency (regardless of immunization history)
- Incompletely immunized individuals 5 years of age and older as indicated in §Part 2 – Immunization of Special Populations, under Specific Immunocompromising Conditions
- Individuals who are at high risk during a cluster/outbreak per Communicable Disease Control Manual, Chapter 1: Haemophilus influenzae type b (refer to 6.1.1 Immunoprophylaxis During an Outbreak among Adults), as determined by the regional MHO in consultation with the Provincial Health Officer and BCCDC

**DOSES AND SCHEDULE:**

**Age at presentation:**

- 2-6 months: 3 doses given as 0.5 mL **IM**, separated by 8 weeks.
- 7-11 months: 2 doses given as 0.5 mL **IM**, separated by 8 weeks.
- 12-14 months: 1 dose given as 0.5 mL **IM**.

**NOTE:** Children completing any of the above primary series require a booster dose. See BOOSTER DOSES.

- 15-59 months: 1 dose given as 0.5 mL **IM**.

All other indications: 1 dose given as 0.5 mL **IM**.

**ADMINISTRATION:**

- Both products need to be reconstituted. Use the diluent provided with the vaccine.
- Administer the entire contents of the reconstituted vaccine.

---

A Children who had Hib disease prior to 24 months of age may not have mounted an adequate immune response for protection against Hib disease and should receive vaccine according to the schedule consistent with their age.

B Although HIBERIX® is not approved for use in those 5 years of age and older, it may be used off-label if indicated (based on expert opinion).

C It is preferable to use the same Hib product for all doses of the primary series. Using different Hib products during the primary series is acceptable if it is not possible to continue with the initial product or the product is unknown.

D If series is interrupted, complete series according to age at which the child re-presents.

E At 15 months of age and older, a single dose of any Hib product is all that is required for protective antibody levels.

F Give vaccine at least 14 days prior to elective splenectomy, or if not possible, 14 or more days post splenectomy. If there is concern that the patient may not present later for immunization, give vaccine before discharge.
Haemophilus b Conjugate Vaccine
Act-HIB® Supplier: Sanofi Pasteur Limited
HIBERIX® Supplier: GlaxoSmithKline Inc.

BOOSTER DOSES:
• One dose given as 0.5 mL IM at 18 months of age. A

SEROLOGICAL TESTING:
Serological testing is not recommended before or after immunization.

CONTRAINDICATIONS:
1. History of anaphylactic reaction to a previous dose of a Hib-containing vaccine or to any component of Act-HIB® or HIBERIX®.

PRODUCT COMPONENTS:
Act-HIB®:
Potential allergens: tetanus protein.
Other components: sucrose, Tris(hydroxymethyl)aminomethane.

HIBERIX®:
Potential allergens: tetanus toxoid.
Other components: lactose.

PRECAUTIONS:
Not applicable.

SPECIAL CONSIDERATIONS:
Hib vaccines may be used interchangeably.

ADVERSE EVENTS:
Local: redness, induration, swelling, pain.
Systemic: fever, irritability, lethargy, loss of appetite, prolonged or abnormal crying, vomiting, diarrhea.

A The booster dose may be given as early as 12 months of age provided there is a minimum interval of 8 weeks following the previous dose.